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Abstract: A 79-year-old woman with a diagnosis of lower 
gastrointestinal bleeding was found to have a complement- 
dependent anti-Jk sup(a) in her serum. The anti-Jk sup(a) was evaluated by the 
antiglobulin technique with polyspecific, anti-C3, and anti-IgG an- 
tihuman globulin (AHG). A variety of Sensitization and detection 
methods were used, including the prewarmed saline technique, 
enzyme treatment of test cells, a low-ionic additive solution (LISS), 
22 percent albumin, Polybrcnc, and an increased scrum/cell ratio. 
The anti-Jk sup(a) was detected only when polyspecific AHG and anti- 
C3 were used compared to anti-IgG, regardless of the selected 
enhancement technique. Anti-C3 gave weaker reactions than 
polyspecific AHG. IgG subclassing was inconclusive. The anti-Jk sup(a) 
was not detected when plasma was substituted for serum. The use 
of polyspecific versus IgG AHG in prctrmsfusion testing is 
discussed. 
In 1951, Allen et al. sup(1) reported the first case of 
hemolytic disease of the newborn (HDN) associated 
with anti-Jk sup(a). Since then, other cases have been 
reported in which anti-Jk sup(a) caused severe HDN sup(2) or, in 
one case, caused no clinical symptoms. sup(3) However, the 
evidence that anti-Jk sup(a) 4-6 and -Jk sup(b) 7 cause acute and 
delayed hemolytic transfusion reactions is well 
documented. 
Kidd system antibodies are often difficult to iden- 
tify, as they are rarely potent, can show a dosage effect 
by reacting more strongly with Jk(a+b-) than with 
Jk(a + b +) cells, and frequently become nondetectable 
within a few weeks or months after their initial iden- 
tification. sup(8) Some of the enhancement techniques used 
to identify Kidd system antibodies include the use of 
enzymes, LISS solutions, Polybrene, and an increased 
serum:cell To be clearly detected, some rare 
examples of anti-Jk sup(a) require the use of a polyspecific 
AHG, which contains an anticomplement fraction in 
addition to anti-IgG. 12-16 
Standard immunohematology protocols vary among 
hospitals, blood centers, and reference laboratories 
with regard to alloantibody detection and the routine 
use of polyspecific or IgG AHG. There is no one 
method that will detect all alloantibodies. This case 
report presents comparative data concerning the detec- 
tion and identification of a complement-dependent 
anti-Jk sup(a). The role of anticomplement in AHG for 
pretransfusion testing is discussed. 
Case Report 
A 79-year-old woman was admitted to a hospital 
with a diagnosis of lower gastrointestinal bleeding. The 
hemoglobin level dropped from 10 g/dL to 8.6 gidL 
within four hours and then stabilized at 9 g/dL. The 
hematocrit was 26 percent. The patient's medications 
included Feledene (piroxicam), Carafate (sucralfate), 
and Trazodone (trazodone hydrochloride). A blood 
sample was sent to the blood bank for pretransfusion 
testing. Two of three reagent (screening) red cells, 
tested with the serum, were positive (1+) at the AHG 
phase. Two of four units of blood were likewise incom- 
patible in the major crossmatch. The direct antiglobulin 
test (DAT) performed on the patient's red cells was 
negative. The sample was forwarded to the blood 
center reference laboratory for antibody identification. 
The patient's medical history indicated that several 
units of blood were transfused in 1956 while she was 
being treated for an episode of GI bleeding. The at- 
tending physician confirmed that she had not been 
transfused while under his care for the past three years. 
The patient had been pregnant at least once and had 
undergone a hysterectomy several years before. She was 
placed on iron therapy and was not transfused dur- 
ing this admission. 
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Materials and Methods 
Red cell testing 
Initial testing at the reference laboratory consisted 
of an ABO and Rh phenotype and a DAT with two 
manufacturers' polyspecific antihuman globulins (PS- 
AHGs) (EKA-Organon Teknika Carp., Malvern, PA, and 
Gamma Biologicals, Inc., Houston, TX). A complete 
antigen profile for the common blood group systems 
was also determined with a variety of blood group- 
ing reagents. 
Serum testing 
The patient's serum was tested for alloantibodies us- 
ing a set of two reagent (screening) red cells (Gamma 
Biologicals, Inc.) and a cord and auto control cell at 
the immediate spin Is) and room temperature (RT) 
phases. Two red cell panels were tested: an untreated 
inhouse saline panel of donor red cells (WARC 1-86), 
and a commercial ficin-treated red cell panel (Gam- 
ma Biologicals, Inc.). The untreated panel was tested 
by a strict saline prewarmed technique with 
polyspecific AHG (Gamma Biologicals, lnc.) as 
described elsewhere.' In this laboratory, saline is pre- 
warmed to 40-41 °C. The ficin panel was tested at 
IS, 37 °C, and AHG, using IgG-AHG (BCA-Organon 
Teknika Corp.). A 2-3 percent red cell suspension was 
used for all test procedures. 
Selected Jk(a+b-), Jk(a+b+), and Jk(a-bc) test cells 
were repeatedly tested with the patient's serum by the 
prewarmed technique using anti-IgG from three dif- 
ferent manufacturers (American Red Cross, Rockville, 
MD; BCA-Organon Teknika Corp.; and Gamma 
Biologicals, Inc.). Selected red cells were also tested 
with anti-C3 (Immucor, Inc., Norcross, GA). Those test 
cells were read at the antiglobulin phase immediately 
after centrifugation and also after a 10-minute RT in- 
cubation. Different enhancement media tested includ- 
ed: L I S  additive solution (Immucor, Inc.), 22 percent 
albumin (BCA-Organon Teknika Corp.), and Polybrene 
as described by Lalezari and Jiang. sup(11) All reagents were 
prepared in our laboratory. All tests using the LlSS ad- 
ditive solution and 22 percent albumin were incubated 
at 37 °C for 30 minutes. 
Plasma was tested with duplicate sets of three 
Jk(a+b-) red cells and one Jk(a+b+) red cell by the 
prewarmed technique. PS-AHG was added at the an- 
tiglobulin phase to one set, and IgG-AHG was added 
to the remaining set. 
The serum:cell ratio was increased from 2:l  to 4:1 
and tested with Jk(a+b-) and Jk(a+b+) red cells. 
Studies to detect hemolysis were performed as 
described by Mollison. sup(17) Ten percent washed cell 
suspensions of Jk(a+h-), Jk(a+b+), Jk(a-b+), and 
autologous cells were prepared. One part red cells to 
two parts patient serum and fresh serum from a group 
O donor were incubated at RT for one hour. The 
serum:cell mixtures were then centrifuged and exam- 
ined for hemolysis. An aliquot of the patient's serum 
was referred to the Special Services Laboratory at the 
Holland Laboratories of the American Red Cross for 
IgG subclassing and monocyte monolayer assay. 
All testing followed standard blood banking 
techniques9 or was performed according to the 
manufacturer's instructions. The reactions were grad- 
ed according to our standardized protocol, similar to 
that published by Marsh. sup(18) 
Results 
The patient's red cells typed as group O, Rh-negative, 
and had a microscopically positive DAT with 
polyspecific AHG. The DAT with monospecific anti- 
IgG (heavy chain specific) and with anti-C3 was 
negative. An eluate was not prepared, as the patient 
had not been recently transfused. The red cell 
phenotype was as follows: C-E-c + e + , M + N-S + s + , 
P sub(1) +, k(a-b+), K + ,  Fy(a-b+), Jk(a-b+). 
The antibody screening, cord, and auto control cells 
were negative at IS and after a 30-minute RT incuba- 
tion. An anti-Jk sup(a) was detected with the untreated 
prewarmed panel using PS-AHG. The ficin-treated 
panel was negative at 37 °C and at the antiglobulin 
phase using IgGAHG. Two of 10 ficin-treated red cells 
were weakly positive at IS but had no apparent 
specificity. The patient's serum was retested with the 
ficin-treated panel and a PS-AHG serum was substituted 
at the antiglobulin phase. An anti-Jk sup(a) was clearly 
demonstrable (1 to 3+). The anti-Jk sup(a) reactivity did not 
show dosage with either untreated or ficin-treated 
panel cells. 
The results of the initial study and additional studies 
done with different manufacturer's IgG-AHG and 
enhancement media are outlined in Table 1. The same 
threeJk(a+b-)red cells and oneJk(a+b+) red cell were 
used for the additional testing to maintain consistent 
antigen expression. The anti-Jk sup(a) was not detected us- 
ing the prewarmed panel when three different 
manufacturer's IgG-AHG were used; however, weak 
anti-Jk sup(a) reactivity was observed with an anti-C3 
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reagent. The patient's serum reacted with five of seven 
Jk(a+ b-) red cells at 37 C with a LISS additive solu- 
tion, but no reactivity was detected at the antiglobulin 
phase using IgG-AHG. The anti-Jk sup(a) was not detected 
with a 22 percent albumin-37 °C-IgG technique, nor 
by using Polybrene (IS followed by IgG-AHG). Although 
22 percent albumin is not truly an enhancement 
medium for sensitization, it was included in this study 
because many regional hospitals use it in their testing 
protocol. 
No reactivity was observed when the patient's 
plasma was tested against both Jk(a+b-) and Jk(a+ b+) 
red cells using either PS-AHG or IgG-AHG. The anti- 
Jk sup(a) was not detected when the serum:cell ratio was 
increased to 4:1 using IgG-AHG. The hemolysis studies 
were negative. When the test for IgG subclassing was 
done, red cells incubated with the patient's serum 
reacted with heavy chain-specific anti-IgG but did not 
react with IgG subclass specific reagents. The 
monocyte monolayer assay was not performed due to 
Table 1 
Comparative detection of anti-Jk sup(a) ccording to the 
antihuman globulin (AHG) used and sensitization 
technique employed. 
Technique Test cells 
JK(a+b-) Jk(a+b+) Jk(a-b+) 
Prewarmed AHG 
PS-AHG I to 2 +  2 +  0 
IgG-AHG #A* 0 0 0 
Anti-C3 W ± to I +  W ± to 1+ 0 
#B* 0 0 NT‡ 
#C* 0 0 NT 
Ficin pretreatment 
PS-AHG 1 to 3+ 1 to 2 + 0 
IgG-AHG #A 0 0 0 
LISS additive 
37 °C W ± to 1 + †  0 0 











0 0 0 
0 0 0 
* indicative of different manufacturers sup(1) reagents 
† 517 cells reactive 
‡ Not tested 
insufficient sample volume. 
Discussion 
The importance of the anticomplement fraction in 
polyspecific antihuman globulin (PS-AHG) in the detec- 
tion and identification of the Jk sup(a) antibody at the in- 
direct antiglobulin phase (IAT) in this case report is 
clearly apparent. The antibody was detected only 
when PS-AHG or anti-C3 were used. The anti-Jk sup(a) w a s  
not detected at the IAT phase with a monospecifrc anti- 
IgG (heavy chain specific) reagent when enzymes, LISS, 
22 percent albumin or Polybrene were used. When 
plasma was tested instead of serum, anti-Jk sup(a) reactivi- 
ty was not apparent. Increased reactivity with Jk(a + b-) 
and Jk(a+b+) cells with anti-C3, although slight, was 
observed after a 10-minute incubation at RT. These 
results emphasize the role of anticomplement in the 
detection and identification of this example of anti- 
Jk sup(a) at the IAT phase. 
Since Löw and Messeter sup(19) first introduced the LISS 
procedure, LIS as either an additive or wash solution 
has become a well-accepted technique for use in de- 
tecting alloantibodies. The manual Polybrene pro- 
cedure has not achieved the same level of routine use 
as LISS but has been accepted as an alternative techni- 
que (DeLong EN. Unpublished data). Lalezari and 
Jiang sup(11) reported that an anti-Jk sup(a) titer could be 
increased from 25 to 100 with Polybrene. A study 
published by Steane et al. sup(20) proposed that a manual 
Polybrene test was a rapid, sensitive, and suitable test 
for compatibility. The anti-Jk sup(a) presented in this case 
report was not detectable when either LISS or 
Polybrene was used. Both of these procedures usually 
use anti-IgG at the antiglobulin phase to prevent non- 
specific agglutination. 
Kidd system antibodies are predominantly lgG3, but 
can also be a mixture of IgG1 and IgG3.sup(17) This ex- 
ample of anti-Jk sup(a), when tested at the Holland 
laboratory of the Red Cross, was determined to be IgG 
in composition however, attempts to further categorize 
the IgG subclass were unsuccessful. 
In the study by Howard et al., sup(13) eight antibodies 
were detected primarily or only hy AHG containing 
anticomplement activity. Anti-IgG gave weak or 
negative reactions. Seven of the eight antibodies were 
anti-Jk sup(a) or -Jk sup(b) and three were implicated in delayed 
hemolytic transfusion reactions or shortened the sur- 
vival of incompatible sup(51)Cr-labeled red cells. However, 
Nance et al. sup(12) studied a complement-dependent anti- 
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Jk sup(a) in a patient who received five units of Jk(a+) red 
cells that did not appear to be clinically significant. 
A flow cytofluorometry method was used to monitor 
red cell survival. The survival rate of the Jk(a+) 
transfused cells was found to be comparable to the ex- 
pected value for normal red cell survival (38% vs. 
37%, respectively). In a case described by Mollison 
and Newlands, sup(21) a splenectomized patient with a 
complement-dependent anti-Jk sup(a) slowly but pro- 
gressively destroyed transfused Jk(a+ b +) cells over a 
three-week period instead of the typical seven days 
seen with many delayed transfusion reactions. 
Because our patient had not been recently transfused 
or splenectomized, one cannot determine whether this 
example of anti-Jk sup(a) would be clinically significant in 
vivo. It i s  of interest that this patient's immune system 
continues to produce a relatively potent Jk sup(a) antibody, 
considering that the last transfusion was probably over 
20 years ago. Issitt reports a case in which an anti-Jk sup(a), 
with a titer of 64, continued to be produced by a pa- 
tient 16 years after exposure to Jk(a+) red cells. sup(8) The 
significance of the patient's weakly positive DAT is 
unknown. 
Many hospital blood banks in our region use IgG- 
AHG, and a few routinely use EDTA plasma for all 
pretransfusion testing (DeLong EN. Unpublished data). 
These blood banks would not have detected this ex- 
ample of anti-Jk sup(a) at the IAT phase and, statistically, 
would have likely transfused Jk(a+) red cells. However, 
one must keep in mind that a complement-dependent 
anti-Jk sup(a) detectable solely by PS-AHG is considered to 
be relatively rare. sup(14) The advantages and disadvantages 
of polyspecific and IgG AHG have been debated over 
the years, most notably by Petz and Garratty, sup(22) 
Howard et al., sup(13) Wright and Issitt, sup(15) and Beck and 
Marsh. sup(23) The decision to use PS-AHG or IgG-AHG is 
in part a matter of personal preference and may be 
based on whether the cost of investigating clinically 
insignificant complement-binding antibodies would 
outweigh the risk of missing a rare complement- 
binding antibody that may he clinically significant. 
Another aspect of the decision-making process 
depends on whether the immunohematology testing 
is being performed in a hospital blood bank, donor 
center, or reference laboratory In a hospital, one must 
consider what is appropriate and practical for a transfu- 
sion service and then select methods which will iden- 
tify the alloantibodies predominantly found in the pa- 
tient population served. A donor center is primarily 
62 
interested in detecting clinically significant alloan- 
tibodies in the healthy donor population while 
reference laboratories are prepared to evaluate unusual 
antibodies that are either not readily identified, react 
serologically in an unpredictable fashion, or are dif- 
ficult to isolate from a sample containing multiple an- 
tibodies. The resources and methods used in a 
reference laboratory are more extensive than those 
used in most hospital blood banks or transfusion 
services and therefore are more likely to find an 
unusual antibody of questionable in vivo significance. 
It is not the author's intent to recommend one type 
of AHG or one alloantibody detection technique over 
another. Rather, it is to remind immunohematologists 
that, as the trend in pretransfusion testing is toward 
less testing, as with the abbreviated crossmatch, one 
must evaluate the current methodologies to determine 
what is appropriate and practical and what will pro- 
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Educational and scientific posters 
M. S. KENNEDY 
Many associations and societies are encouraging 
poster presentations instead of oral presentations at 
meetings. However, posters prepared by professionals 
can he costly ($200 and up). Neat, easy-to-read, and 
attractive posters that can be prepared at a low cost 
are desirable. Instructions follow for the preparation 
of such posters. 
Materials and Methods 
Decide on a title for the poster presentation and then 
organize the information to he presented into introduc- 
tion, materials and methods, results, and conclusions, 
as for an oral presentation. Write each section con- 
cisely, including enough information to clarify the 
points. Simple tables and diagrams are helpful to the 
audience. Diagrams may be beyond your artistic skill, 
but tables can easily be done using methods presented 
here. 
In a commercial artists’ supply store (see the yellow 
pages), buy a package of colored construction paper 
(all one color). Each sheet of paper is 9” x 12”, so 30 
sheets would be needed to cover a 4‘ x 6‘ poster 
display area. For a stiffer backing, poster board (all one 
color) can he used. One 28” x 44” poster hoard usually 
costs less than $2. Two and one-half sheets of poster 
board will cover the 4‘ x 6’ display area. If the store 
has a cardbard cutter, you’re in luck; otherwise, a long 
steel ruler and a knife will he needed. Cut each of the 
colored poster hoards into eight 11“ x 14” pieces. 
Buy transfer letters (Prestype®, Chartpak®) in 
84-point type for the title and in 48-point type for the 
authors and institutions. Helvetica Medium is a good 
type style to choose. For the title, select white poster 
board or smooth-finish, white drawing paper. Cut in- 
to appropriately sized 6” x 12”, 6” x 14”, or 9“ x 11” 
pieces, to show a colored border above, below, and 
at extreme ends when each is glued or pinned to the 
colored poster hoard or construction paper (see Fig. 
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